Gemini Therapeutics, Inc.

NasdaqGM:GMTX Stock Report

Mkt Cap: US$58.5m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Gemini Therapeutics Past Performance

How has Gemini Therapeutics performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: GMTX is currently unprofitable.

Growing Profit Margin: GMTX is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: GMTX is unprofitable, and losses have increased over the past 5 years at a rate of 22% per year.

Accelerating Growth: Unable to compare GMTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GMTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (53%).

Return on Equity

High ROE: GMTX has a negative Return on Equity (-41.52%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies